OrbiMed’s Terns Pharmaceuticals TERN Stock Holding History

OrbiMed’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,153,300	Closed	-$87M	–	130
2025 Q4	$87M	Sell	2,153,300 -5,409,671	-72%	-$125M	1.78%	15
2025 Q3	$56.8M	Hold	7,562,971	–	–	1.33%	21
2025 Q2	$28.2M	Hold	7,562,971	–	–	0.7%	37
2025 Q1	$20.9M	Hold	7,562,971	–	–	0.5%	42
2024 Q4	$41.9M	Hold	7,562,971	–	–	0.86%	33
2024 Q3	$63.1M	Sell	7,562,971 -56,164	-0.7%	-$462K	1.15%	26
2024 Q2	$51.9M	Hold	7,619,135	–	–	1.02%	31
2024 Q1	$50M	Hold	7,619,135	–	–	0.92%	39
2023 Q4	$49.4M	Hold	7,619,135	–	–	0.99%	37
2023 Q3	$38.3M	Hold	7,619,135	–	–	0.81%	46
2023 Q2	$66.7M	Hold	7,619,135	–	–	1.21%	31
2023 Q1	$90.2M	Hold	7,619,135	–	–	1.77%	16
2022 Q4	$77.6M	Buy	7,619,135 +137,931	+2%	+$918K	1.48%	22
2022 Q3	$44.1K	Buy	7,481,204 +3,690,000	+97%	+$13.7M	0.82%	45
2022 Q2	$9.4K	Hold	3,791,204	–	–	0.17%	92
2022 Q1	$11.3M	Hold	3,791,204	–	–	0.18%	96
2021 Q4	$26.8M	Hold	3,791,204	–	–	0.34%	69
2021 Q3	$39.5M	Hold	3,791,204	–	–	0.43%	64
2021 Q2	$46.5M	Hold	3,791,204	–	–	0.47%	60
2021 Q1	$83.4M	Buy	+3,791,204	New	+$83.1M	0.78%	38

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

OrbiMed's TERN Position: Q1 2026 in Review

OrbiMed sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 2,153,300 shares — an estimated $87M sold.

OrbiMed first reported a position in TERN in Q1 2021 and held it in 20 quarters. The position peaked at $90.2M in Q1 2023. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

OrbiMed reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
OrbiMed sold 2,153,300 Terns Pharmaceuticals shares in Q1 2026, an estimated $87M.
OrbiMed first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 20 quarters.
OrbiMed's Terns Pharmaceuticals position peaked at $90.2M in Q1 2023.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.